CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
1,327
1,327
29,575
7,894
2,173
Cost of Revenue
204
204
-
-
-
Gross Profit
1,123
1,123
-
-
-
Operating Expenses
Research Development
19,630
19,630
18,537
15,073
15,658
Selling General and Administrative
11,770
11,770
11,665
10,756
16,819
Total Operating Expenses
31,400
31,400
30,202
25,829
32,477
Operating Income or Loss
-30,277
-30,277
-627
-17,935
-30,304
Interest Expense
3,339
3,339
-
-
-
Total Other Income/Expenses Net
669
669
1,003
-275
-466
Income Before Tax
-32,947
-32,947
376
-18,210
-30,770
Income from Continuing Operations
-32,947
-32,947
376
-18,210
-30,770
Net Income
-32,947
-32,947
376
-18,210
-30,770
Net Income available to common shareholders
-32,947
-32,947
376
-18,210
-30,770
Basic EPS
-
-
0.01
-0.39
-0.81
Diluted EPS
-
-
0.01
-0.39
-0.81
Basic Average Shares
-
-
58,492
46,507
38,171
Diluted Average Shares
-
-
59,907
46,507
38,171
EBITDA
-
-29,608
-449
-17,935
-30,304